We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
As was the case yesterday and this morning the maximum availability is just £2200
Good observation Hopoist ...i like it
Just need a little bit more trading volume.....
Yes I've been reading them....thank you.
PYC starting to hire additional staff to help manage new contracts is a positive and hopefully paves the way for further expansion....
No-one who was around at the time will forget when the original "personalised medicine RNS" came out and the SP exploded!
Hello hopist
And add to the fact its one of only a few stocks that INCREASED revenues in H1 + expected to hit £900,000 income for year ended June and pipeline of contracts now worth £1.5mln (the same as the current market value !)
Also read some of Ant123 posts,PYC seem to be at cutting edge of precision medicine
Bid is currently 1.101p on HL. And a triple bottom on the chart at 1.075. Hopefully a hammer candle by close of play today, which is a strong signal. Ticking up slowly....
Finally managed to buy more , HL was not giving a quote for large periods this morning , not sure if same applies to other people
I used my name because I founded the company.
Hi Ant,
Shame you didn't get a reply. Perhaps if your wife applied in her own name and used the company website careers section you might get some joy? It seems a shame to waste the opportunity.
Brilliant Post Ant - Thank You
Thank you Ant fr that great post.
So, PYC did not reply, not even to say thanks but not thanks? That is poor to be honest?
Is only £3200 today
Super post Ant
Alot to take in...thanks for taking the time
DeBull my wife was a Biotech analyst in The City. Keen to see the company prosper and not just for personal gain she asked me to communicate her willingness to help The Biostats development at PYC. She is also a data analyst and has previously written a paper An Algorithm to predict Protein Protein Binding when at Downing College Cambridge it has ben cited internationally. Cogent in Python and C I asked the Company if they would like some help. We didn't get a reply and I assumed that they had employed all the "muscle" they required. Which is a shame has her contacts extend into the sector where there are numerous opportunities to grow the business. I am not being critical at all but when companies like Avacta are undertaking PK and PD testing in Clinical Trials as indeed OXB we should be banging on their doors. PYC has shown that it understands the need to keep the market better informed and so I look forward to more announcements in the short to medium term. As I previously said DoseMeRX could be a game changer bur as with everything timing is always critical, others will follow suit and USP's and first to market edge are then lost. I have added a few more at these levels it makes sense to me as Personalised Medicine is definitely the way forward.
Focused on the delivery of biostatistics projects. Several complementary options are being pursued simultaneously to build out this new capability and a further update will be provided to the market towards the end of the current financial year
Dr Putcha was appointed as Head of Bio-statistics on 3rd October, 2023. Over six months later and we have heard nothing and he does not appear on the list of Team members on the company website
Maybe he is being kept back for the big Bio-statistics update promised sometime before 30th June ?
I have reached out to them, but apart from a cordial reply, nothing about the subject in hand.
I can only go on the reply JM gave to a IM some months ago about why BOD dont see buying stock as the best way to grow the business?
Be interesting to hear Ant15's take on this?
Meanwhile, are we heading sub 1p?
Not as yet, but will consider doing so
If you don't mind me asking have you set out your thoughts to Peter? It sounds like he'd be receptive to shareholders
I have noted this before, but there is a similarity in parts of the wording used by Physiomics and Valirx. I feel it is not a coincidence. Here is the latest example :
PYC tweet 4th April 'Our latest news roundup .....' whilst Valirx tweet 9th April 'Welcome to the latest edition of our news roundups'
JM commented in the most recent IMC presentation that 'our financial and operational success is not dependent on what happens at Valirx'. I would take this to mean that there are no imminent plans for any closer ties between the two, which is good to know
Very early days I know, but the benchmark by which I will be judging Peter Sargent's performance as CEO is the company share price. Price on the trading day immediately before he was appointed (21st January) was 1.80. Price now 1.10
I like what I have seen and heard to date in his presentations and I am hoping that this now starts to feed through to the share price and we get back to at least the pre-appointment levels by financial year end. Some quality RNS releases are
what is now needed
Extremely disappointed that Angel Investor and NED Shalabh Kumar has not put his hand in his pocket and taken a decent chunk of shares by now Same for the rest of the Board of Directors who are happy to accept free options or take shares in a knock-down placing but show no enthusiasm for investing at full price like the rest of us lesser mortals
It would be an excellent way for the BOD to prove to the new Principal Consultant - Head of Modelling in no uncertain terms that they genuinely have big ambitions for growing not only sales but, more importantly, shareholder value
Biostatistics service line
The Company was excited to announce its intention to develop a separate consulting service line focused on the delivery of biostatistics projects. Several complementary options are being pursued simultaneously to build out this new capability and a further update will be provided to the market towards the end of the current financial year. We anticipate that, if successful, this new service line could make a material contribution to the Company's revenues
Ant
I share that view too, plus the biostatistics division looks very exciting and Peter wording interesting
Added a few more this am I think the DoseMe Rx is a game changer .